These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31308062)

  • 1. Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.
    Tinker AV; Hirte HW; Provencher D; Butler M; Ritter H; Tu D; Azim HA; Paralejas P; Grenier N; Hahn SA; Ramsahai J; Seymour L
    Clin Cancer Res; 2019 Oct; 25(20):6052-6060. PubMed ID: 31308062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
    Patel SP; Alonso-Gordoa T; Banerjee S; Wang D; Naidoo J; Standifer NE; Palmer DC; Cheng LY; Kourtesis P; Ascierto ML; Das M; Diamond JR; Hellmann MD; Carneiro BA
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
    Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
    Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
    Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
    J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
    Catenacci DVT; Rasco D; Lee J; Rha SY; Lee KW; Bang YJ; Bendell J; Enzinger P; Marina N; Xiang H; Deng W; Powers J; Wainberg ZA
    J Clin Oncol; 2020 Jul; 38(21):2418-2426. PubMed ID: 32167861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Liu J; Burris H; Wang JS; Barroilhet L; Gutierrez M; Wang Y; Vaze A; Commerford R; Royer-Joo S; Choeurng V; Humke E; Moore K
    Gynecol Oncol; 2021 Dec; 163(3):473-480. PubMed ID: 34627611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
    J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
    Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
    Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
    Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.